Our focused screen resulted in the identification and validation of several compounds targeting proteins in several known mechanisms in human AD such as DLK, GSK3, CDK5, and Fyn kinase, all of which are current pathways of interest in drug development. The gene discussed is CDK5; the disease is Alzheimer disease.